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Introduction
A ‘thrombin-like’ activity, first identified by chromogenic
assays in some prothrombin complex concentrates, may
be associated with a 65 – 70 kDa protein of unusual
chromatographic behaviour (Hunfeld et al., 1999). This
enzyme was termed plasma hyaluronan binding serine
protease (PHBSP) because it represented the functional
enzyme of a truncated, catalytically inactive plasma
hyaluronan-binding protein (Choi-Miura et al., 1996). A
serine protease identical to PHBSP has recently been re-
ported to activate plasminogen activators (Römisch et al.,
2000) and FVII in a tissue factor-independent way
(Römisch et al., 1999). Furthermore, in vitro-data showed
that FV and FVIII are inactivated by this protease (Römisch
et al., 1999, and our own unpublished observation). There-
fore, a pro- and anticoagulatory, as well as a profibrinolytic
potency is attributed to PHBSP. For all these functions,
however, a physiological relevance remains to be shown.
PHBSP is a trypsin-like protease consisting of 537
amino acids in its mature proenzyme form (Choi-Miura
et al., 1996). In the N-terminal part (propeptide or ‘activa-
tion segment’; Khan and James, 1998) three epidermal
growth factor-like and one kringle domain are present, in
the C-terminal part the catalytic triade is found. A total con-
centration of 12 µg/ml (200 nM) PHBSP in plasma was de-
termined by quantitative ELISA (Römisch et al., 2001). The
proenzyme undergoes an intermolecular autocatalytic ac-
tivation by cleavage at an internal Arg290-Ile bond (Etscheid
et al., 2000) resulting in an N-terminal 48 kDa heavy chain
and a C-terminal 30 kDa light chain held together by a sin-
gle disulfide bond. PHBSP activity and proenzyme activa-
tion in vitro are effectively inhibited by plasma serpins, es-
pecially α2-antiplasmin and C1-esterase inhibitor.
The single-chain plasminogen activator-activating po-
tency and the strong inhibition of PHBSP by C1-esterase
inhibitor (Hunfeld et al., 1999; Römisch et al., 2000) indi-
cated catalytic similarities between PHBSP and the con-
tact phase enzyme plasma kallikrein (PK). Very little is
known about the interaction of PHBSP with components
of the contact activation system (plasma kallikrein/kinin
system). This system participates in important physiolog-
ical processes like the surface-dependent, intrinsic path-
way of blood coagulation, in fibrinolysis, in angiogenesis
and in processes like inflammation or blood pressure reg-
ulation (Colman and Schmaier, 1997; Schmaier, 2000;
Colman, 2001). The major components of the kallikrein/
kinin system are high molecular weight kininogen (HK,
Williams-Fitzgerald-Flaujeac factor), plasma prekallikrein
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The influence of the hyaluronan-binding protease
(PHBSP), a plasma enzyme with FVII- and pro-uroki-
nase-activating potency, on components of the con-
tact phase (kallikrein/kinin) system was investigated.
No activation or cleavage of the proenzymes involved
in the contact phase system was observed. The pro-
cofactor high molecular weight kininogen (HK), how-
ever, was cleaved in vitro by PHBSP in the absence of
any charged surface, releasing the activated cofactor
and the vasoactive nonapeptide bradykinin. Glyco-
soaminoglycans strongly enhanced the reaction. The
cleavage was comparable to that of plasma kallikrein,
but clearly different from that of coagulation factor
FXIa. Upon extended incubation with PHBSP, the light
chain was further processed, partially removing about
60 amino acid residues from the N-terminus of do-
main D5 of the light chain. These cleavage site(s) were
distinct from plasma kallikrein or FXIa cleavage sites.
PHBSP and, more interestingly, also plasma kallikrein
could cleave low molecular weight kininogen in vitro,
indicating that domains D5H and D6H are no prerequi-
site for kininogen cleavage. PHBSP was also able to
release bradykinin from HK in plasma where the pro-
cofactor circulates predominantly in complex with
plasma kallikrein or FXI. In conclusion, PHBSP repre-
sents a novel kininogen-cleaving and bradykinin-re-
leasing enzyme in plasma that shares significant cat-
alytic similarities with plasma kallikrein. Since they
are structurally unrelated in their heavy chains
(propeptide), their similar in vivo catalytic activities
might be directed at distinct sites where PHBSP could
induce processes that are related to the kallikrein/
kinin system.
Key words: Contact phase system /
Glycosoaminoglycans /Kinin /Kininogenase /PHBSP /
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(PPK, Fletcher factor) and the coagulation factor XII (FXII,
Hageman factor). Within the intrinsic coagulation cas-
cade, the coagulation factor XI (FXI) is closely associated
with the contact activation system (Donaldson et al.,
1976; Cochrane and Griffin, 1979; Kaplan, 1979). C1 es-
terase inhibitor is considered as the major regulator of the
surface-mediated contact phase system (Cameron et al.,
1989; Colman, 2001).
HK is a single chain glycoprotein of 120 kDa, com-
posed of 626 amino acids, comprising the domains D1-
D4, D5H and D6H. In plasma HK is mostly found in com-
plex with PK or FXI, mediated by domain D6 (Mandle
et al., 1976; Thompson et al., 1977). The activated forms
of both zymogens, plasma kallikrein (PK) and FXIa, can
cleave the pro-cofactor HK to finally release the vasoac-
tive peptide bradykinin (BK), although the cleavage pat-
terns differ (Scott et al., 1985; Mauron et al., 2000). Unlike
FXIa, BK release by plasma kallikrein leaves behind acti-
vated kininogen (HKa) which has anti-adhesive and anti-
angiogenic functions (Colman, 2001). Low molecular
weight kininogen (LK) is a 66 kDa single chain glycopro-
tein representing a splicing variant transcribed from the
same single-copy gene as HK, yielding identical domains
D1 to D4. The procoagulatory PK- and FXI-binding do-
main D6H is missing in LK, and domain D5L is only 4 kDa
in length and its amino acid sequence is unrelated to D5H
of HK (Takagaki et al., 1985). FXI and PPK are structural-
ly related proteins sharing 58% amino acid sequence
identity (De La Cadena et al., 1994). The binding regions
for HK have been mapped to apple domains A1, A2, and
A4 of PK (Page et al., 1994; Renné et al., 1999) and A1,
A2, and A4 of FXI (Baglia et al., 1990; Renné et al., 2002),
respectively. PK consists of an N-terminal heavy chain of
52 kDa that is disulfide-linked to two light chain variants
(36 or 33 kDa). This PK, designated α-kallikrein (PKα),
can catalyze an autolytic cleavage within the second ap-
ple domain generating β-kallikrein (PKβ), which has a
similar FXII-activating potency but a diminished rate of
cleavage of HK (Colman et al., 1985). 
Here we demonstrate that the hyaluronan-binding ser-
ine protease from human plasma represents a novel
kininogen-cleaving enzyme, and we show that also in
plasma the vasoactive nonapeptide bradykinin is released
from kininogen. The cleavage mechanism is compared to
that of other kininogen processing plasma enzymes. We
further investigated whether besides high molecular
weight also low molecular weight kininogen could function
as a substrate for PHBSP and whether glycosoaminogly-
cans (GAGs) affect kininogen cleavage by PHBSP. The
physiological relevance of the findings is discussed. 
Results
Proenzymes of the Contact Activation System
In order to evaluate the influence of PHBSP on the con-
tact activation system the purified proenzymes of this
system were incubated with PHBSP. When commercially
available preparations of PPK, FXI and FXII (each at a fi-
nal concentration of 2.8 µM) were treated with 78 nm
PHBSP no cleavage products could be observed by
SDS-PAGE (Figure 1A). Also at equimolar ratio no cleav-
age was detectable (not shown) indicating that none of
these proenzymes is a substrate of PHBSP. From these
results it was concluded that PHBSP does not directly
participate in the regulation of the enzymes of the contact
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Fig. 1 Effect of PHBSP on Components of the Kallikrein/kinin
System.
(A) Plasma prekallikrein (PPK) and the coagulation factors FXI
and FXII were incubated with PHBSP for 90 min at a substrate to
enzyme ratio of 35:1. Samples were subjected to SDS-PAGE un-
der reducing conditions and the gel was stained with coomassie
brilliant blue. PPK (lane 1 and 2), FXI (lane 4 and 5) and FXII (lane
7 and 8) are shown each before and after treatment with PHBSP.
As controls, plasma kallikrein (PK, lane 3), FXIa (lane 6), and
FXIIa (lane 9) are shown. The results are representative of at least
two independent experiments. (B) Gel analysis of HMW kinino-
gen treated with PHBSP or plasma kallikrein. The fragment sizes
of the pre-stained molecular weight marker (New England Bio-
labs, Leusden, The Netherlands) are indicated. This gel is repre-
sentative of at least three independent experiments.
Fig. 2 Ligand Binding Assay.
The concentration-dependent binding of PPK, PKβ and PHBSP
to immobilized HMW kininogen was studied in an ELISA assay.
Each data point represents the mean of four measurements ±
SD.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 13:42
activation system. Lanes 3, 6, and 9 show PK, FXIa and
FXIIa for comparison. The lack of a visible heavy chain of
52 kDa in the commercial PK preparation (lane 3) indicat-
ed that it is apparently not the α-form but mostly the β-
form, presumably as result of autolproteolytic cleavage
during preparation or storage. A strongly reduced HK-
binding potency of the PKβ used in this study compared
to an equal amount of PPK was found in a ligand-binding
assay (Figure 2). In the same assay PHBSP exhibited only
a very weak affinity for HK. Thus, the lack of both en-
zymes to bind to HK allowed to compare only their cat-
alytic activities, independent of the strong complex for-
mation between PKα and HK. 
Cleavage of HMW Kininogen in Solution
When the procofactor HMW kininogen (HK) was incubat-
ed with PHBSP under identical conditions as described
for the zymogens of the kallikein/kinin system, the reduc-
tion of the 120 kDa procofactor band and the generation
of two bands of approximately 62 and 47 kDa was ob-
served, generating a cleavage pattern indistinguishable
from that obtained with plasma kallikrein (Figure 1C).
From here we started a more detailed study of the HK-
cleaving property of PHBSP in comparison to the well-
described HK-processing enzymes, PK and the coagula-
tion factors FXIa and FXIIa. 
In a time course the cleavage of purified procofactor
HK by these enzymes in the absence of a surface reac-
tant was analyzed side-by-side. The reaction products
were subjected to reducing SDS-PAGE and Western blot
analysis with a HK-specific polyclonal antibody. The in-
cubation of HK with PKβ or PHBSP (Figure 3A, C) result-
ed in the disappearance of the 120 kDa procofactor band
and in the generation of a ~62 kDa band doublet, pre-
sumably the heavy chain and a slightly faster migrating
intermediate of the light chain. Both enzymes further
processed the intermediate, concomitant with the ap-
pearance of a ~47 kDa band, the expected mature light
chain of activated HK (HKa). The PHBSP-mediated
cleavage products, including the intermediate, were sim-
ilar in size to the products generated by cleavage of HK
with plasma kallikrein. 
PHBSP (and PKβ) showed a different cleavage pattern
compared to FXIa. The treatment of HK with FXIa showed
the generation of a ~62 kDa heavy chain. The intermedi-
ate of the light chain was not visible (Figure 3B). The in-
cubation of HK with FXIa for more than 1 h resulted in the
disappearance of the mature light chain, presumably by
further cleavage at Lys502-Thr503 removing both surface
binding regions from the light chain as reported earlier
(Scott et al., 1985; Mauron et al., 2000). This cleavage
step was not observed with PHBSP or PKβ. From the
data presented above it was concluded that PHBSP
Cleavage of Kininogen by PHBSP 1635
Fig. 3 Western Blot Analysis of HK Cleavage.
The rates of HK processing by (A) plasma kallikrein, (B) FXIa and (C) PHBSP are shown. One hundred ng of HK, treated as indicated,
was loaded on a Laemmli gel under reducing conditions and was transferred to a PVDF membrane. The products were immunodetect-
ed with an anti-HK antibody and were visualized using a chemiluminescent substrate. The incubation time is indicated below the bot-
tom gel. Untreated HK (U) and HK treated for 4 h in buffer (U4) are also shown. The further processing of the HK light chain by PHBSP
is enlarged for better visibility. (D) Additional PHBSP-specific cleavage products. HK (15 µg), treated either with PHBSP or PKβ, were
separated by SDS-PAGE and the gel was Coomassie Brilliant Blue-stained. The results shown in panels A, C, and D are representative
of at least three independent experiments, the experiment shown in panel B was repeated once with the same result. The positions of
the heavy chain (hc) and the light chain (lc) of HKa are indicated. The N-terminal sequences of two 7 kDa bands, generated by PHBSP,
are shown on the left.
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cleaves HK in a similar way as PK but clearly different
from FXIa. 
FXIIa, structurally related to PHBSP, has been reported
to cleave HK in prekallikrein-deficient plasma in the pres-
ence, but not in the absence of kaolin to yield cleavage
products very similar to those generated by PK (Wiggins,
1983). Our studies revealed that in the absence of kaolin
FXIIa did not cleave HK (data not shown). In contrast,
cleavage of HK by PHBSP was not dependent on acti-
vating surfaces and was therefore clearly different to the
activation of HK by FXIIa. 
Cleavage Sites on HK
Amino-terminal sequencing by Edman degradation of the
47 kDa light chain generated by PHBSP yielded the se-
quence KHNLGH, demonstrating that PHBSP cleaved
the intermediate at the same Arg419-Lys420 bond as PK.
Similar to PK, PHBSP removed a 47 amino acid residue
polypeptide (Ser372-Arg419) from the intermediate 62 kDa
fragment to release the mature light chain (Lys420-Ser626). 
Additional Cleavage of the Light Chain of HK
During incubation of HK for several hours with PHBSP
the mobility of the light chain increased, best seen in the
sample after 4 h incubation (compare Figure 3A and C,
blow-up). In order to identify additional cleavage site(s),
15 µg HK were treated for 4 h with PHBSP or PK and was
subsequently separated on a 10 – 20% SDS-PAGE for
low molecular weight proteins. Repeatedly two frag-
ments of approximately 7 kDa became visible (Figure 3D)
which were not present upon 4 h treatment of HK with
PKβ. Partial amino acid sequence analysis revealed that
the N-termini of both 7 kDa fragments, KHNLG, were
identical, representing the N-terminus of the mature light
chain of HK. The location of the additional PHBSP-cleav-
age site(s) have still to be determined. A size of 7 kDa
would correspond to approx. 60 amino acid residue pep-
tides, hence reaching from Lys420 to a lysine- and histi-
dine-rich domain at Lys480 within the second surface
binding region of the D5H domain (De La Cadena et al.,
1994). 
Release of Kinin
In a radioimmunoassay with bradykinin-specific antibod-
ies the completeness and the rate of the kinin release by
PHBSP and PKβ was compared. Additionally, in this ex-
periment it was investigated whether low molecular
weight kininogen (LK) can function as substrate for PHB-
SP or plasma kallikrein. From master incubation mixtures
of HK or LK with PHBSP or PKβ aliquots were withdrawn
at specific time points, ethanol-precipitated to remove
the high molecular weight proteins, and the concentra-
tion of free kinin in the vacuum-dried ethanol supernatant
was determined (Figure 4). In each aliquot withdrawn
from the reaction mixture 27 pmol kininogen were pres-
ent. The cleavage of HK by PHBSP released ~20 pmol
kinin (~80%) within 60 min, a complete release of kinin
was observed after 120 min. PK completely released the
kinin after 15 min already. The time course showed that
with identical substrate to enzyme ratios (35:1) the re-
lease of kinin by PK occured at a much faster rate com-
pared to PHBSP.
Low molecular weight kininogen (LK) showed repeat-
edly a slightly faster mobility upon treatment with PHBSP
or PKβ in PAGE and immunoblot analysis (not shown). To
further substantiate these observations, LK was included
in the kinin release experiments. The results of the ra-
dioimmunoassay demonstrated that both, PHBSP and
PKβ could process LK to release kinin. In contrast to HK,
in the rate of kinin release from LK no significant differ-
ence between PK and PHBSP was detectable. The lack
of the PK-binding D6H domain in LK did not prevent
cleavage of LK by PKβ. Only the rate and completeness
of cleavage was affected. Whether the use of soley PKα
compared to PKβ would result in a more pronounced dif-
ference in the rate of cleavage of HK and LK has not been
determined during his study. In summary, the identical LK
hydrolysis rate of both enzymes, PHBSP and PKβ, further
supports the assumption that they have very similar cat-
alytic properties. 
Identity of the Kinin
The results of the radioimmunoassay confirmed the re-
lease of kinin from HK or LK. However, whether it was
the nonapeptide bradykinin, the decapeptide kallidin
(Lys-bradykinin) or smaller BK-metabolites could not be
clearly answered because the anti-BK antibody used for
detection did not discriminate between these kinin
forms. Using MALDI-TOF mass spectrometry, in the
ethanol supernatant of PHBSP-treated HK a peak corre-
sponding to 1060.69 was detected, confirming that
1636 M. Etscheid et al.
Fig. 4 Kinin Release.
The rate of kinin release from HMW kininogen (HK) and LMW
kininogen (LK) by PHBSP and PKβ was analyzed in a quantita-
tive radioimmunoassay. The data for HK represent one of two in-
dependent experiments which yielded identical results. For
comparison, kinin release from LK was once included. Each data
point represents the average of two measurements.
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bradykinin (NH2-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-
COOH; Mr=1060.22) was generated (Figure 5A). Another
signal of 904.50 might represent desArg-BK. A peak of
1076.72 corresponds to the mass of BK with an addi-
tional hydroxyl group, most likely at the C4 of the proline
located on the amino side of a glycine, yielding [Hyp3]-
BK (Mr=1076.2; Sasaguri et al., 1988). All the BK-related
peaks were also observed when PKβ was used as en-
zyme (Figure 5B), once more confirming the catalytic
similarity betweeen PK and PHBSP. Two possibilities de-
scribe the origin of the desArg-BK peak. It could result
from partial hydrolysis of the Arg263-Pro264 bond in HK in-
stead of the Lys362-Arg363 bond in the second cleavage
step of HK processing, thus liberating desArg1-BK. One
hour treatment of synthetic bradykinin with PHBSP or
PKβ, however, did not result in the removal of Arg1 from
BK as determined by MALDI-TOF mass spectrometry
(not shown). Another possibility would be that BK is par-
tially metabolized by traces of kininase I (carboxypepti-
dase N) removing the C-terminal arginine residue and
generating desArg9-BK (Murphey et al., 2000). As ex-
pected, the cleavage of LK by PHBSP or PKβ also re-
sulted in the release of BK as determined by MALDI-TOF
mass spetrometry (data not shown).
Influence of GAGs on Kininogen Cleavage
The affinity of PHBSP to hyaluronic acid and glyco-
soaminoglycans (GAGs) like heparin and the function of
proteoglycans containing heparan sulfate or chondroitin
sulfate (HS and CS) as cell surface receptors for HK (Ren-
né et al., 2000; Renné and Müller-Esterl, 2001) raised the
question whether kininogen cleavage may be promoted
Cleavage of Kininogen by PHBSP 1637
Fig. 5 MALDI-TOF Mass Spectrometric Analysis of Kinin Re-
leased from HMW Kininogen.
(A) Incubation of HK with PHBSP; (B) incubation with PKβ. The
masses of peaks corresponding to bradykinin (BK) and related
metabolites, desArg-BK and hydroxyproline-BK ([Hyp3]-BK) are
indicated. 
Fig. 6 Effect of Glycosoaminoglycans on Kininogen Activation.
Cleavage of HK by PHBSP (ratio 35:1) was studied in the pres-
ence of increasing concentrations of the GAGs heparin, heparan
sulfate (HS), and chondroitin sulfate (CS) as indicated. Cleavage
proceeded for 10 min at room temperature and aliquots corre-
sponding to 60 ng HK were subjected to PAGE and immunoblot
analysis. Each gel is representitive of at least three independent
experiments. 
Fig. 7 Cleavage of HMW Kininogen in Human Plasma.
Ten µl freshly donated and citrated plasma was inubated for 90
min with one µl of PHBSP in a final concentration as indicated
below each lane. The plasma samples were separated by SDS-
PAGE under reducing conditions and were transferred to a PVDF
membrane. HK and the BK moiety were immunodetected with
(A) an anti-HK polyclonal antibody (α-HK pAb), or (B) an anti-BK
polyclonal antibody (α-BK pAb). In the 120 kDa pro-cofactor
(HK) the BK moiety was not immunodetectable, but was de-
tectable in cleaved kininogen (HKa). LMW kininogen (66 kDa)
comigrated with serum albumin and was not detectable by im-
munoblot under the chosen conditions. 
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by GAGs. When HK cleavage was studied as function of
HS, CS or unfractionated heparin a concentration-de-
pendent increase of kininogen cleavage was found by
PAGE and Western blot (Figure 6). At >1 mg/ml CS,
~0.5 – 2 mg/ml HS or 0.025 – 0.25 mg/ml heparin
(~5 – 47 IU/ml) a maximum of HK cleavage was found, in-
dicating that an optimum concentration of these charged
molecules facilitate cleavage of HK by PHBSP. The effect
of CS was less pronounced compared to HS or heparin.
Interestingly, in an earlier study a maximum of autocat-
alytic activation of proPHBSP was found at a heparin
concentration of 5 – 10 IU/ml with an approximately 6-
fold increase in activation (Etscheid et al., 2000). This im-
plicates that at a similar optimum concentration of
charged GAGs like heparin two important physiologic
processes would be promoted, autoactivation of the zy-
mogen and cleavage of a natural substrate. Whether the
in vitro effects of HS, CS and heparin are of biological im-
portance, e.g. on the surface of endothelial or other cells,
deserves further investigations.
Cleavage of HK in Human Plasma
The in vitro findings presented above indicated that HK is
processed by PHBSP in solution to finally liberate
bradykinin and activated cofactor, HKa. Consequently
we addressed the question whether HK, circulating in
plasma in complex with PK or FXI, could be a substrate
for PHBSP. When citrated pool plasma was incubated for
90 min with increasing concentrations of purified PHBSP
(31.25 nM– 4 µM), significant cleavage of HK could be ob-
served only at rather high PHBSP concentrations of 2 µM
or above (Figure 7A). At 4 µM PHBSP an almost complete
processing of HK was detected. Using a BK-specific an-
tibody (Figure 7B) it was observed that upon cleavage of
HK a 62 kDa band was generated, presumably the heavy
chain with the BK moiety attached to its C-terminus. This
occured already at PHBSP concentrations below the
plasma concentration of proPHBSP (200 nM). An addi-
tional BK-specific ~75 kDa band (asterisk in Figure 7B)
was also found upon incubation of plasma with purified
PKβ, the identity of this band is still unclear. Our data
clearly demonstrate that PHBSP has the potency to
cleave the contact phase procofactor HK present in plas-
ma, albeit quantitatively only at elevated, non-physiolog-
ic concentrations and prolonged incubation. Whether LK,
circulating in plasma at a concentration of 1.3 µM, is also
cleaved by PHBSP has not been determined during this
study.
Next, the cleavage of HK in plasma was studied time-
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Fig. 8 Time Course of Kinin Release by PHBSP Activity in Plasma.
The cleavage of HK by 3 µM PHBSP added to human plasma was analyzed by Western blotting with an anti-HK polyclonal antibody and
with an anti-BK polyclonal antibody (A) as described in Figure 5. The time of incubation is indicated below each lane. The position of un-
cleaved HK is indicated by an arrow. (B) Radioimmunoassay of the time-course of kinin release. Each data point represents the average
of two measurements. (C) Identity of the kinin. The supernatant of ethanol-precipitated human plasma that had been incubated for 90
min in the absence (top) or in the presence of 3 µM PHBSP (bottom) was analyzed by MALDI-TOF mass spectrometry. Peaks corre-
sponding to BK and BK metabolites are labeled.
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resolved at a fixed concentration of PHBSP (3 µM). Soy-
bean trypsin inhibitor and the ACE inhibitor captopril
were present at 1 µM and 10 mM, respectively, to inhibit
PK and to prevent metabolization of BK by angiotensin
converting enzyme (ACE). Upon addition of PHBSP the
procofactor band disappeared instantly concomitant
with the generation of the 62 kDa BK signal (Figure 8A)
and free kinin (Figure 8B). A complete release of BK from
the kininogen heavy chain was not observed. Under the
chosen conditions PHBSP was able to release 100 nM
kinin within the first min of incubation. At prolonged incu-
bation, however, a total of ~240 nM kinin were released.
Based on the total concentration of HK + LK in plasma,
2 µM, PHBSP completely processed >10% of plasma
kininogens. 
Finally we determined by MALDI-TOF mass spectrom-
etry which BK metabolites could be found. Comparing
plasma incubated for 60 min at RT in the absence or
presence of PHBSP (Figure 8C) showed clearly the gen-
eration of peaks corresponding to BK (Mr=1060.60), des-
Arg-BK (Mr=904.53), [Hyp3]-BK (Mr=1076.60) and a peak
identical to BK1 – 7 (Mr=757.51) all of which were not vis-
ible in the PHBSP-free control. The generation of small
BK metabolites BK1 – 7 and BK1 – 8 (desArg-BK) could
be expected because in plasma BK has a rapid turnover
with a half life of only 17 s (Murphey et al., 2000). In sum-
mary, our data unequivocally demonstrate that PHBSP
cleaves HK (and presumably LK) in plasma and gener-
ates the vasoactive peptide bradykinin.
Discussion
The results of our study demonstrate that PHBSP has the
potency to activate high and low molecular weight
kininogen in vitro. The predominant products of cleavage
of HK by PHBSP (Figure 9) are comparable to those gen-
erated by plasma kallikrein. Additionally we found that
both, PHBSP and PKβ, can use LK as substrate releasing
BK and cleaved LK with the small light chain remaining
attached to the heavy chain of LK by a disulfide bridge.
Treatment of HK with PHBSP for prolonged time partially
lead to further cleavage of the light chain in domain D5H,
removing at least the first surface and cell binding region
from HKa. Unlike PK and PHBSP, FXIa inactivates the co-
factor by removing both surface binding regions from the
light chain, hence separating the D5H from the D6H do-
main and thus abolishing the procoagulatory function of
HKa (Scott et al., 1985; Mauron et al., 2000). The removal
of only the N-terminal part of the surface binding domain
D5H by PHBSP might be involved in the regulation of HK
functions at cell surfaces where interactions with pep-
tides up to Lys480 are required, e.g. in proliferation and mi-
gration of endothelial cells (Colman et al., 2000) or in the
binding of HK to neutrophils (Khan et al., 1998).
When PHBSP was added to human plasma an almost
complete cleavage of HK was observed, including the
dominant fraction of HK that circulates in plasma in com-
plex with prekallikrein or FXI. Apparently, prekallikrein
and FXI bound to HK do not affect cleavage of HK by
PHBSP. The data presented here suggest that cleavage
of HK in plasma by physiological concentrations of PHB-
SP (proPHBSP = 200 nM) is unlikely to release significant
amounts of BK. At sites of increased (pro)enzyme and re-
duced inhibitor concentrations, however, e.g. at GAGs on
cell surfaces or in the perivascular environment, the situ-
ation would presumably be different. The propensity of
PHBSP to bind to GAGs like hyaluronic acid (Choi-Miura
et al., 1996), the major component of the extracellular
matrix (Laurent and Fraser, 1992) or to heparin, raises the
possibility that autoactivation of the zymogen and kinino-
gen cleavage with concomitant BK release could be di-
rected to cell surfaces or to the extravascular environ-
ment. Although BK release by PHBSP in solution was
less complete compared to PKβ, the amount of BK re-
leased would presumably be sufficient to produce a local
effect, e.g. on cell surfaces. In plasma HK and LK are
present at concentrations of 0.66 µM and 1.3 µM, respec-
tively, and >100 nM free kinin were found within 1 min of
incubation of plasma with PHBSP. Already 3 nM BK, how-
ever, can be sufficient to stimulate cellular responses
(Busse and Lamontagne, 1991). Furthermore, cultured
human umbilical vein endothelial cells (HUVECs) can ex-
Cleavage of Kininogen by PHBSP 1639
Fig. 9 Domain Structure and PHBSP Cleavage of Kininogens.
The single-chain precursors HK and LK as well as the products
generated by PHBSP are shown. HK and LK are transcribed
from the same single copy gene as unique mRNAs by alternative
splicing (Takagaki et al., 1985). The structure and characteristics
of the domains are shown as described recently (Zhang et al.,
2000; Colman, 2001). The termini generated by PHBSP are indi-
cated. The fragment released from the D5H domain of HKa by
prolonged incubation with PHBSP is shown with dotted lines.
Upon cleavage of LK (LKc) bradykinin is released, while the do-
main D5L remains attached to the heavy chain of LMW kininogen
by a single disulfide bridge (Kellermann et al., 1987).
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press HK on their surface at a concentration of approxi-
mately 9×103 HK molecules/cell (Schmaier et al., 1988),
and express 1×107 HK binding sites/cell (Zhao et al.,
2001), thus locally increasing the concentration of HK on
cell surfaces. Two GAGs, heparan sulfate and chondroitin
sulfate have been described as cell surface receptors of
kininogen (Renné et al., 2000; Renné and Müller-Esterl,
2001), and in this study they promoted HK cleavage by
PHBSP in vitro. Therefore a locally elevated concentra-
tion of HSPGs or CSPGs might promote HK activation by
PHBSP. 
The ability of PHBSP and PK to activate both, kinino-
gens and prourokinase (sc-uPA) (Römisch et al., 2000),
indicates that PHBSP has an overlapping substrate
specificity with PK. Cleavage of FXII, which is a substrate
of PK, was not observed for PHBSP. In contrast, activa-
tion of FVII and inactivation of FVIII or FV were found for
PHBSP (Römisch et al., 1999) but not for PK, indicating
that they do not share all enzymatic activities.
The heavy chain of PHBSP consists of three epidermal
growth factor-like domains and one kringle domain,
whereas the heavy chain of PK possesses four apple do-
mains, three of which are involved in HK-binding (Page
et al., 1994; Renné et al., 1999). Binding experiments
showed that PHBSP has only a weak or no affinity to HK.
In plasma proPHBSP most likely does not form stable
complexes with HK, whereas PPK and FXI are found pre-
dominantly associated with HK (Mandle et al., 1976;
Thompson et al., 1977). Through this interaction sub-
strate and proenzyme are in close proximity, facilitating
activation of the plasma kallikrein/kinin system, e.g. on
endothelial cells (Rojkjaer and Schmaier, 1999). The
structural differences in the heavy chain may direct the
function of PK and PHBSP to different locations, where
they exhibit similar activities.
It can be hypothesized that HK expressed on endothe-
lial cells or bound to cell matrix (Colman et al., 1985)
rather than HK circulating in blood in complex with PPK
or FXI would be a substrate for PHBSP. BK liberated from
bound HK could stimulate its endothelial cell receptor B2
to trigger subsequent intracellular reactions like the re-
lease of intracellular Ca2+ (Busse and Fleming, 1996). In-
deed, recent studies demonstrated the PHBSP-mediat-
ed release of Ca2+ from endogeneous stores in cultured
HUVECs, a process that was dependent on the prote-
olytic activity of PHBSP. Interaction with the protease-ac-
tivated receptors PAR 1 – 4 could be excluded during this
study (Storck et al., 1999). Since HK and HK receptors
are synthesized in cultured endothelial cells and are ex-
pressed on the cell surface (Schmaier et al., 1988) the
PHBSP-dependent Ca2+ release in HUVECs might be at-
tributed to the liberation of BK from cell- or matrix-bound
HK. Further experiments are required to support this hy-
pothesis. 
While scuPA is autocatalytically inactive and does not
cleave HK, it can be speculated that surface-bound
proPHBSP autoactivates and promotes HK or sc-uPA
activation and thus initiates subsequent reactions:
(i) promoting the binding of HK to cell surface receptors.
On endothelial cells HKa, but not HK can bind to do-
main 2 and 3 of the urokinase receptor (uPAR) in a zinc-
dependent reaction. The generation of HKa and bind-
ing of HKa to uPAR (Colman et al., 1997) are initial
steps in cell adhesion, proliferation and angiogenesis
(Chavakis et al., 2000; Colman et al., 2000; Sheng
et al., 2000).
(ii) Activation of surface-bound sc-uPA. This would result
in plasmin generation on the cell surface, initiating cell-
associated fibrinolysis.
The surface-bound plasminogen activator-plasmin sys-
tem plays a pivotal role in the proteolytic cascade result-
ing in the activation of matrix metalloproteases, matrix
degradation and tissue remodeling (Saksela and Rifkin,
1988; Mignatti and Rifkin, 1996). Further investigations
are required to elucidate the in vivo importance of the HK-
and scuPA-activating potency of PHBSP in processes
like fibrinolysis, angiogenesis, inflammation or blood
pressure regulation.
Materials and Methods
Proteins and Antisera
PHBSP was prepared as described recently (Hunfeld et al.,
1999). The goat polyclonal antibody to kininogen was obtained
from ICN (Eschwege, Germany), the rabbit polyclonal anti-
bradykinin antibody used in Western blots was from Affiland
(Ans-Liege, Belgium), horseradish peroxidase-conjugated sec-
ondary antibodies were from Sigma (Deisenhofen, Germany).
The kininogens and all proenzymes and enzymes were pur-
chased from Calbiochem (Bad Soden, Germany) unless stated
otherwise.
Gel Electrophoresis and Western Blot Analysis
Samples were separated by SDS-PAGE according to Laemmli
(1970) and proteins were visualized by Coomassie Brilliant Blue
staining of the gel. For Western blot analyses of HK processing,
100 ng HK were loaded to the gel and were transferred to a
PVDF membrane (Millipore, Eschborn, Germany). HK and its
processing products were visualized by immunodetection using
a kininogen- or a bradykinin-specific antibody. After incubation
with secondary antibodies the labeled proteins were detected
with the chemiluminescent substrate ECL (Amersham-Pharma-
cia, Freiburg, Germany).
Amino Acid Sequence Analysis
After complete cleavage, 15 µg HK was equally distributed into
3 lanes of a 5 – 20% Laemmli gel and separated under reducing
conditions. The protein was transferred to a PVDF membrane
and the protein bands were visualized by Coomassie Brilliant
Blue staining. The N-terminal amino acid sequence was deter-
mined by Edman degradation on an Applied Biosystems Procise
Sequencer as described earlier (Hunfeld et al., 1999).
Cleavage Reactions
HMW and LMW kininogen (2.7 µM each), respectively, were in-
cubated at room temperature with 78 nm of enzyme in cleavage
buffer (50 mM Tris-HCl, 150 mM sodium chloride, 10 mM calci-
1640 M. Etscheid et al.
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um chloride and 0.1% Tween 20, pH 7.8). For gel analysis iden-
tical volumes were withdrawn at the specified time points and
were immediately added to 1/3 vol gel loading buffer (1% SDS,
2% mercaptoethanol, 0.02% bromophenol, 10% glycerol) and
boiled for 5 minutes. Samples were subjected to SDS-PAGE
and Western blot analysis. The cleavage of HK was also stud-
ied as function of the GAGs heparan sulfate, chondroitin sul-
fate, and heparin at identical enzyme to substrate ratio as de-
scribed above. The reaction proceeded for 10 min at room
temperature. The reaction was stopped by adding 1/3 vol. gel
loading buffer, and 60 ng HK was subjected to PAGE and im-
munoblot analysis.
Radioimmunoassay
Incubation of HK or LK with PHBSP or PKβ was performed as
described above. At each time point 10 µl (corresponding to
27 pmol HK) were withdrawn and added to 40 µl of a stop solu-
tion (50 mM Tris-HCl, 150 mM NaCl, 40 mM EDTA, 4 mM ortho-
phenanthroline, pH 7.8). Immediately, this solution was added to
950 µl 96% ethanol, incubated at 70°C for 10 min, followed by
rapid cooling on ice and sedimentation for 5 min at 12000 g at
4°C in a Heraeus Biofuge (Hanau, Germany). The pellet was re-
extracted with 96% ethanol and treated as above, and the com-
bined supernatants were evaporated in a speed vac (Eppendorf,
Hamburg, Germany). The amount of kinin present in the super-
natant was determined by radioimmunoassay as described in
Fink et al.(1985).
Mass Spectrometric Analysis
The kinin-containing fraction of the samples was obtained as
described above. The masses of peptides in the evaporated su-
pernatant were determined by matrix-assisted laser desorp-
tion/ionization-time of flight (MALDI-TOF) mass spectrometry in
a 3,5-dimethoxy-4-hydroxycinnamic acid matrix on a BIFLEX III
system (Bruker Saxonia Analytik, Leipzig, Germany) using the
reflection mode. The mass (m/z ratio) of each fragment was cal-
culated by comparing the experimental data to molecular weight
standards that were used for calibration as recommended by the
manufacturer.
HK Binding Assays
The wells of a 96 well microtiter plate (Maxisorb; Nunc, Wies-
baden, Germany) were coated overnight at 4°C with 100 µl of
10 µg/ml HK in coating buffer (35 mM NaHCO3, 15 mM NaCl, pH
9.6), blocked with 2% BSA overnight at 4°C, and incubated for
1 h at 37°C with 100 µl of a geometrical dilution series of the pro-
tein of interest (1 – 0,156 µg/ml). After washing 4 times with
HBS + 0.1% Triton X-100 the bound ligands were fixed by incu-
bation with 2% formaldehyde for 20 min at room temperature
and were detected by subsequent addition of anti-PHBSP or
anti-PK primary and POD-labeled secondary antibodies. The
development of the substrate 3,3‘,5,5‘-tetramethylbenzidine
(Sigma, Deisenhofen) proceeded for 30 min and the absorption
at 450 nm was determined in an ELISA reader (SLT, Offenburg,
Germany).
Cleavage of Kininogen in Human Plasma
Undiluted citrated pool plasma was incubated for 90 min at
room temperature with 1/10 vol of a dilution series of PHBSP (fi-
nal concentration: 4 µM– 31.25 nM). The reaction was stopped by
adding 90 µl of gel loading buffer including ß-mercaptoethanol
and boiling for 10 minutes. Samples were loaded on a 5 – 20%
gel for SDS-PAGE. After protein transfer to a PVDF membrane,
HK or BK were visualized by immunodetection. Additionally, the
identity of the free kinin was determined by MALDI-TOF mass
spectrometry.
Alternatively, in a time course experiment plasma was treated
with 3 µM PHBSP in the presence of 1 µM soybean trypsin in-
hibitor (Roche Pharmaceuticals, Mannheim, Germany) to su-
press potential PK activity and 10 mM captopril (Sigma) to pre-
vent bradykinin metabolisation by angiotensin converting
enzyme (ACE). At various time points (0 – 240 min) samples were
withdrawn and analysed by western analysis, radioimmunoas-
say, and MALDI-TOF mass spectrometry as described above.
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